Mr. Grippo joined Catalent as vice president of Corporate Development in 2016, and in his new role will oversee the strategy and corporate development functions of the company, as well as Catalent’s scientific team. Prior to joining Catalent, Mr. Grippo was vice president of Corporate Development for CR Bard. He also held a similar leadership role with Hill-Rom Holdings. Earlier in his career he held positions with SG Cowen and UBS Securities.
Additionally, Julien Meissonnier has been named vice president and chief scientific officer, and will report to Mr. Grippo. In this new role, Mr. Meissonnier will join the executive leadership team, leading Catalent’s new product development and technology innovation programs. He will also head up the company’s scientific community and customer advisory partnerships to help improve formulation and adoption of drug delivery technologies. Mr. Meissonnier will continue to co-chair the Catalent Applied Drug Delivery Institute to leverage emerging new therapeutic modalities.
Mr. Meissonnier previously served as vice president, Science and Technology, and led Catalent’s European softgel R&D team.
“Since our IPO in 2014, we have completed seven acquisitions and are expected to close the acquisition of an oral dose and biologics facility in Italy, from Bristol-Myers Squibb, before the end of the calendar year,” said John Chiminski. “The decisions to make strategic investments in areas such as biologics, gene therapy, and spray drying have been driven in large part by the work of our Corporate Development team, led by Mike Grippo in partnership with key leaders across the business.” He added, “During his long career with Catalent, Julien has been instrumental in driving excellence across the R&D community, notably through the launch of the Scientific Resource Center serving the business’s team of approximately 2,400 scientists and technicians. He will promote open innovation within the organization, and we welcome both to the executive leadership team.”